Autoantibodies: A common finding in chronic hepatitis C virus (HCV) infection

Riezu-Boi, JI; Crisóstomo, S; Sánchez-Ibarrola, A; Maluenda,; Larrea, Esther; Camos, J; Garcı́a, Nicolás; Castilla, Alberto; Mp, Civeira; Prieto, J.

doi:10.1016/0168-8278(91)91624-p

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with CHC and co-existent autoantibodies, mainly LKM-1, appear to be more frequent in Europe than in other parts of the world. In most studies the prevalence of LKM-1 is < 5% [67][68][69][216][217][218][219][220][221][222][223][224]. Treatment of such patients with corticosteroids and immunosuppressive drugs is usually not effective, particularly if RIBA and serum HCV RNA are positive; in fact, it may even enhance HCV replication [229,230].…”

Section: Treatment Of Chronic Hepatitis C With Co-existent Autoimmunimentioning

confidence: 99%

The spectrum of extrahepatic manifestations in hepatitis C virus infection

Hadziyannis

1997

Journal of Viral Hepatitis

135

View full text Add to dashboard Cite

Infection with the hepatitis C virus affects not only the liver but also non-hepatic tissues and may combine with many unrelated diseases and morbid conditions. A number of extrahepatic manifestations have already been recognized. For some of the extrahepatic disorders their association with HCV infection is well established while for others it remains probable or weak. Here, emphasis is given to the well-established extrahepatic manifestations of mixed cryoglobulinaemia, thyroid abnormalities and lichen planus as well as to the newly recognized association with diabetes mellitus, thrombocytopenia and the antiphospholipid syndrome. Pathogenetic mechanisms of extrahepatic and autoimmune features in HCV infection are still unclear and therapeutic decisions in such conditions are difficult. Data on the efficacy and side-effects of therapy with interferon-alpha and corticosteroids are reviewed and some practical guidelines for treatment are given.

show abstract

Section: Treatment Of Chronic Hepatitis C With Co-existent Autoimmunimentioning

confidence: 99%

The spectrum of extrahepatic manifestations in hepatitis C virus infection

Hadziyannis

1997

Journal of Viral Hepatitis

135

View full text Add to dashboard Cite

show abstract

Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom

et al. 1996

Self Cite

View full text Add to dashboard Cite

Antiphospholipid antibodies are a type of autoantibodies that have been implicated in the occurrence of thrombocytopenia and thrombotic events and have been described in autoimmune disorders and diverse viral diseases. In this study anticardiolipin antibodies (immunoglobulin G [IgG] isotype) were determined in serum from 100 patients with chronic hepatitis C and 52 healthy controls. In addition, hepatitis C virus (HCV) markers (anti-HCV and HCV RNA) were investigated in 73 patients with thrombotic disorders and no clinical evidence of liver disease; of these patients 37 cases tested negatively for anticardiolipin antibodies and 36 positively. Anticardiolipin test was positive more frequently (22%) in the group of patients with chronic hepatitis C than in healthy controls (1.9%; P < .001). Using conditional logistic-regression analysis we found that in hepatitis C patients the presence of thrombocytopenia, portal hypertension and the existence of prior thrombotic episodes were significantly related to positivity for anticardiolipin antibodies (P < .05 in all cases). In patients with no evidence of liver disease and a history of thrombotic events, hepatitis C markers were absent in all cases who tested negatively for anticardiolipin antibodies (n = 37), but were present in 16.7% of those positive for anticardiolipin (n = 36) (P = .01). In conclusion, anticardiolipin antibodies are frequently found in patients with chronic hepatitis C and in these patients they may be implicated in the occurrence of thrombosis and in the development of thrombocytopenia. Occult HCV infection is present in a significant proportion of patients with thrombotic disorders and positive for anticardiolipin (the antiphospholipid syndrome).

show abstract